Ascendis Pharma

Ascendis Pharma is a global biopharmaceutical company based in Denmark that utilizes its proprietary TransCon technology platform to develop therapies designed to improve safety, efficacy, and patient convenience. The TransCon, or transient conjugation, platform works by masking active molecules and then releasing them in a predictable manner within the body, aiming to create best-in-class product candidates. The company focuses primarily on areas such as endocrinology, including rare diseases like hypoparathyroidism and achondroplasia, as well as oncology, while also maintaining collaborations for other therapeutic areas and markets.

The company’s development pipeline includes marketed products such as YORVIPATH for hypoparathyroidism and SKYTROFA for pediatric growth hormone deficiency. By addressing unmet medical needs through its technology-driven approach, Ascendis Pharma aims to make a meaningful difference for patients, caregivers, and healthcare providers. The company operates globally with research and development facilities in Europe and the United States, managing its clinical programs and market expansions to support its integrated biopharmaceutical business model.